{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:12:47Z","timestamp":1775635967775,"version":"3.50.1"},"reference-count":63,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2008,7,9]],"date-time":"2008-07-09T00:00:00Z","timestamp":1215561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    This study was performed to investigate the efficacy and safety of a prevention\u2010of\u2010flare\u2010progression strategy with pimecrolimus cream 1% in children and adolescents with atopic dermatitis (AD).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods\u2002<\/jats:bold>\n                    A 26\u2010week multi\u2010centre, randomized, double\u2010blind, vehicle\u2010controlled study was conducted in 521 patients aged 2\u201317\u00a0years, with a history of mild or moderate AD, who were clear\/almost clear of disease before randomization to pimecrolimus cream 1% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a0256) or vehicle cream (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a0265). Twice\u2010daily treatment with study medication was started at the first signs and\/or symptoms of recurring AD. If, despite the application of study medication for at least 3\u00a0days, AD worsened (as confirmed by the investigator), treatment with a moderately potent topical corticosteroid (TCS) was allowed in both groups. The primary efficacy end point was the number of days on study without TCS use for a flare.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    The mean number of TCS\u2010free days was significantly higher (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt; 0.0001) in the pimecrolimus cream 1% group (160.2\u00a0days) than in the control group (137.7\u00a0days). On average, patients on pimecrolimus cream 1% experienced 50% fewer flares requiring TCSs (0.84) than patients on vehicle cream (1.68) (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0&lt;\u00a00.0001). Patients on pimecrolimus cream 1% also had fewer unscheduled visits (87) than patients on vehicle cream (246).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions\u2002<\/jats:bold>\n                    In children and adolescents with a history of mild or moderate AD but free\/almost free of signs or symptoms of the disease, early treatment of subsequent AD exacerbations with pimecrolimus cream 1% prevented progression to flares requiring TCS, leading to fewer unscheduled visits and reducing corticosteroid exposure.\n                  <\/jats:p>","DOI":"10.1111\/j.1468-3083.2008.02785.x","type":"journal-article","created":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T05:42:03Z","timestamp":1215495723000},"page":"1290-1301","source":"Crossref","is-referenced-by-count":36,"title":["Effectiveness and safety of a prevention\u2010of\u2010flare\u2010progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis"],"prefix":"10.1111","volume":"22","author":[{"given":"B","family":"Sigurgeirsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ferr\u00e1ndiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Andriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Grinienko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Pimecrolimus 1% cream in (paediatric) Eczema: Prevention of Progression multi\u2010centre investigator study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,10]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12193-9"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321020-00003"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.76.2.159"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2702.1997.tb00310.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000012309"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.117010"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92474-0"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.12.1530"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21060"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.106484"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.031"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta4370"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.08.003"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/000992280003900101"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70080-5"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410033781"},{"key":"e_1_2_8_18_2","first-page":"624","article-title":"Adverse effects from topical corticosteroids","volume":"21","author":"Hill CJ","year":"1978","journal-title":"Cutis"},{"key":"e_1_2_8_19_2","first-page":"1130","article-title":"Potential hazards of topical steroid therapy","volume":"137","author":"Stoppolino G","year":"1983","journal-title":"Am J Dis Child"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.12968\/hosp.2001.62.3.1531"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1984.tb01124.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1986.tb06242.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb02461.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1988.tb00904.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04076.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2340\/0001555575269271","article-title":"Comparison of the effect of hydrocortisone, hydrocortisone\u201017\u2010butyrate and betamethasone on collagen synthesis in human skin in vivo","volume":"75","author":"Haapasaari KM","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000211513"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02646.x"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.01827.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0846.2001.70203.x"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12053.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.010"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1976.01630330015002"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1979.tb01905.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12260665"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1986.tb02258.x"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1996.tb01070.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03473.x"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018495"},{"key":"e_1_2_8_40_2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1742-1241.2003.tb10492.x","article-title":"Pimecrolimus: a review of preclinical and clinical data","volume":"57","author":"Graham\u2010Brown RAC","year":"2003","journal-title":"Int J Clin Pract"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00269.x"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.122187"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065863"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.126500"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.1.e2"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01383.x"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.65"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.08.015"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.09.016"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04133.x"},{"issue":"2","key":"e_1_2_8_51_2","first-page":"109","article-title":"Pimecrolimus (Elidel\u00ae, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic dermatitis","volume":"15","author":"Harper J","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2006.00398.x"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.88.11.969"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.08.046"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1159\/000086739"},{"key":"e_1_2_8_56_2","unstructured":"FoodandDrug Administration: FDA News.FDA approves updated labeling with box warning and medication guide for two eczema drugs Elidel and Protopic. [WWW document] 2006. URLhttp:\/\/www.fda.gov\/bbs\/topics\/news\/ 2006\/NEW01299.html(last accessed: 30 April 2008)."},{"key":"e_1_2_8_57_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non\u2010parametric estimation from incomplete samples","volume":"36","author":"Kaplan EL","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/68.2.373"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02234.x"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.2307\/2556126"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.2307\/2683975"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1987.10478478"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-1188"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08484.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2008.02785.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2008.02785.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:43:57Z","timestamp":1696949037000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2008.02785.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,10]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1468-3083.2008.02785.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02785.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1157367.617517","asserted-by":"object"}]},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,10]]}}}